This study is currently not recruiting participants.

Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)

S
Scott Fretzin, MD

Primary Investigator

Not Recruiting
18 years - 64 years
All
Phase N/A
1 Location

Brief description of study

The purpose if thus study is to look at immune responses to the tetanus/diphtheria/pertussis and meningitis vaccines in patients with atopic dermatitis who are treated with dupilumab.

Detailed description of study

This is a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: atopic dermatitis
  • Age: 18 years - 64 years
  • Gender: All
Updated on 01 Aug 2024. Study ID: ICO1-14-125 Fretzin

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team